Fig. 7: Effect of Tat-Cx43266-283 (Tat-Cx43) and temozolomide (TMZ) treatment on immune and tumor cells at 7- and 28-days post-implantation (dpi).
A UMAP visualization of all cells collected, colored by treatment and annotations. B Barplot showing the distribution of cell types obtained in untreated and treated animals. C Venn diagram showing the overlap between differentially expressed genes across treatments in the immune cell cluster at 7 dpi. Differential gene expression was analyzed using Wilcoxon test with a p-value cutoff=0.05. See Table S12 for full list. D Top 10 enriched terms from gene ontology (GO) gene sets in immune cell cluster from Tat-Cx43266-283-treated mice compared to the control (see Table S13 for full list). E Violinplots showing early (high levels in controls at 7 days) and late (high levels in controls at 28 days) immune scores in immune cells at 28 days post-implantation under different treatments. F Two-dimensional representation of the cellular states described by Neftel et al.6 in tumor cells of temozolomide-treated mice at 28 dpi. Each quadrant corresponds to one cellular state and each dot represents a cell. G Barplot showing the percentage of cycling cells analyzed, calculated as the sum of percentages of cells in S and G2/M phases, in control and TMZ-treated tumor cells at 28 dpi. H Heatmap showing the expression of selected cytokines and checkpoint molecules in control and TMZ-treated tumor cells at 28 dpi. I Illustrative TGFß1 immunofluorescence images of brains at 28 days post-implantation in control, Tat-Cx43266-283 and temozolomide (TMZ) treated animals, scale bar: 50 µm. J Quantification of TGFß1 protein levels in the immunofluorescence images. Results are expressed in arbitrary units (a. u.) and are the mean±SEM from three independent experiments from which 5 fields were quantified. *P < 0.05, **P < 0.01 (one-way ANOVA).
